Table 1.
Targets of therapy, role in pathogenesis, and associated pharmaceuticals
| Target | Role in pathogenesis | Clinical Trials in EGIDs | Clinical Trials (Atopic Disease) | Clinical Trials (non-Atopic Disease) |
|---|---|---|---|---|
| IL-5/IL5-R | Activation and Recruitment of Eosinophils | Mepolizumab, Reslizumab, Benralizumab | Mepolizumab, Reslizumab, Benralizumab | Mepolizumab |
| IL-13 | Promote eosinophil recruitments, barrier dysfunction, remodeling | QAX576, RPC4046 | Tralokinumab | Tralokinumab |
| IL-4RA | Maintenance of Th2 inflammatory process | Dupilumab | Dupilumab, AMG 317 | |
| CRTH2 | Recruitment of T-cells | OC000459 | AZD1981, OC459, QAV680 | |
| Siglec-8 |
induction of eosinophil cell death inhibition of mast cell activation |
AK002 | AK001, AK002 | |
| TSLP | Recruitment of basophils, stimulation of IL-4 to promote Th2 | Tezepelumab (AMG 157) | ||
| Integrin alpha4beta7 | Recruitment of T-cells, eosinophils and mast cells | Vedolizumab | ||
| Eotaxin-1, -2, -3 | Recruitment of eosinophils | GW766994 | ||
| TGF-β1 |
Enhance collagen production to promote fibrosis Promote smooth muscle contraction Worsen barrier integrity |
Losartan | Fresolimumab, Losartan |